ペーカー教授は、400件以上の膵臓がんおよび胃がんの手術実績があります。ヒサール・ホスピタル・インターコンチネンタルにて、膵神経内分泌腫瘍の治療を専門としています。
ヘヴェス・シュルメリ准教授（医学博士）は、内科および腫瘍内科の専門医です。2004年にエスキシェヒル・オスマングズ大学で医学士号を取得。イスタンブールのカルタル・ドクター・リュトフィ・クルダル教育研究病院にて内科研修を修了（2005年〜2010年）。その後、同病院にて腫瘍内科の専門研修を修了しました（2014年〜2017年）。
同センターにて腫瘍内科専門医として勤務（2017年〜2023年）。その後、管理・臨床ディレクターを務めました（2023年〜2026年）。臨床上の関心分野は、乳がん、肺がん、婦人科がん、消化器がん、泌尿器がんです。
国際的な査読付きジャーナルに多数の論文を発表。国内外の学会で発表を行っています。専門学会でも積極的に活動しており、数々の賞を受賞しています。
セレフ・コムルジュ教授は、アナドル医療センターのESMO認定腫瘍内科医です。病期診断にガリウム68を用いたPET-CTを必要とする神経内分泌腫瘍の治療を専門としています。
エダ・タンリクル医師は、イスタンブールのAnadolu Medical Centerの臨床腫瘍医です。トルコの専門医試験で全国3位の成績を収めました。タンリクル医師は、化学療法と個別化がん治療を専門としています。ジョンズ・ホプキンス病院と提携している施設で勤務しています。
セザー・サグラム医師は、イスタンブールのゲイリテペ・フローレンス・ナイチンゲール病院の腫瘍内科医です。消化器がんおよび乳がんの治療を専門としています。直腸がんの治療タイミングに関する彼の研究は、世界的な治療プロトコルに影響を与えました。サグラム医師は、標的療法や精密医療技術を用いて、個別の治療計画を策定しています。
ヴォルフガング・ケストラー教授は、ウィーン医科大学腫瘍学部門の副部長です。ガリウム68を用いた高度なPET-CT検査を活用し、精密腫瘍学および標的療法を指導しています。
Forbes Israelは、ブラハール・アリェ医師を国内トップクラスの医師の一人として認定しました。このPET-CT専門医は、ソラスキー医療センターで画像診断を統括しています。
エイナット・エベン＝サピル教授は、ソラスキー医療センターの核医学部門を統括しています。ガリウム68を用いたPET-CTによる神経内分泌腫瘍の検出を専門としています。
フォックス・ヴィオラ博士は、BKZゾーリンゲン血液腫瘍科・緩和医療科の主任医師です。同クリニックは、認定された集学的腫瘍センターです。フォックス博士は、ドイツおよびヨーロッパにおける腫瘍性疾患の薬物療法の第一人者であり、15年以上の臨床経験を有しています。
同博士は、ドイツ腫瘍学・血液腫瘍学会（GDHO）、ドイツ医師会、およびアメリカがん研究学会に所属しています。また、分子生物学の研究にも従事しており、その研究成果はがん治療および分子診断の発展に貢献しています。
主な専門領域は、化学療法、免疫療法、分子標的療法、および放射線療法です。フォックス博士は、革新的な治療法と患者への細やかな配慮で知られています。その取り組みにより、高い治癒率を達成し、同僚からの高い評価を得ています。
セバスチャン・カイル教授は、ゾーリンゲン大学病院の診断・インターベンション放射線科の主任医師を務めています。ガリウム68を用いたPET-CTによる神経内分泌腫瘍の検出を専門としています。
ハサン・ムトル医師は、メディカルパーク・アンタルヤ病院コンプレックスの腫瘍内科医です。免疫療法、がんの標的療法、がん治療における遺伝子研究を専門としています。ムトル医師はハジェテペ大学で医学の学位を取得しました。医学教授の称号を保持しています。ムトル医師は、臓器腫瘍の診断と化学療法に注力しています。
ムスタファ・セルカン・アレムダル医師は、メディカルパーク・アンタルヤ病院コンプレックスの臨床腫瘍医です。複雑な固形腫瘍および血液がんの治療を専門としています。アレムダル医師は、アクデニズ大学で医学の学位を取得し、腫瘍学のフェローシップを修了しました。トルコ臨床腫瘍学会の活動的なメンバーです。
Ercan Ozden医師は、VM Medical Park Pendikの腫瘍内科医兼内科専門医です。乳がん、肺がん、大腸がんなど、幅広いがんの治療を行っています。Ozden医師はイスタンブール大学ジェラフパシャ医学部で訓練を受けました。その後、コジャエリ大学で腫瘍内科のサブスペシャリティを修了しました。
ムハンメド・ムスタファ・アトチ医師は、Liv Hospital Topkapıの腫瘍内科准教授です。大腸がん、乳がん、胃がん、肺がんの治療を専門としています。以前は、ジェミル・タシュジオール教授記念市立病院で教育コーディネーターを務めていました。アトチ医師は、米国臨床腫瘍学会（ASCO）の会員です。
イルファン・ジチン医師は、イスティニエ大学リヴ病院トプカプの腫瘍内科教授です。膠芽腫、肺がん、膵臓腫瘍などの複雑な癌の治療を専門としています。トラキア大学医学部の教授も務めています。ジチン医師は以前、トルコ空軍の医師として勤務していました。
Zhang Jinshan, male, China’s First M.D. in the Radiation Medicine, CCI (Chinese College of Interventionalists) Master Interventionalist, Director of the Department of Former Radiological Diagnosis at Chinese PLA General Hospital(No.3 in China) Ph.D. of Medicine, Nagasaki University, Japan.
1980–1985: Completed doctoral studies at Nagasaki University, Japan
1968–present: Department of Radiology, Chinese PLA General Hospital
1988: Third Prize of the Military Science and Technology Progress Award
1989–present: Member of Radiological Society of North America(RSNA)
1990–2009: Standing Committee Member of the Radiology and Therapeutic Radiology Committee of the PLA
1991: Second Prize of the Military Science and Technology Progress Award
1992–2008: Group Leader of the Group of Intervention of Chinese Journal of Radiology
1992–2015: Standing Editorial Board Member and Editorial Board Member of Journal of Interventional Radiology
1993: Granted the Lifetime Special Government Allowance of the State Council
1993–2012: Deputy Chief Editor of Chinese Journal of Medical Image Technology
1994: Third Prize of the Military Science and Technology Progress Award
1997: Second Prize of the Military Science and Technology Progress Award
1997–2009: Standing Member of Chinese Society of Radiology
1999: Third Prize of the Military Science and Technology Progress Award
1999–2010: Deputy Director Member of Chinese Society of Interventional Oncology
2002: Second Prize of the Military Science and Technology Progress Award
2005: Third Prize of the Military Science and Technology Progress Award
Member of Radiological Society of North America(RSNA)
Standing Member of Chinese Society of Radiology
Group Leader of the Group of Intervention of Chinese Journal of Radiology
Deputy Director Member of Chinese Society of Interventional Oncology
Director Member of Beijing Medical Association Society of Interventional Radiology
Deputy Chief Editor of Chinese Journal of Medical Image Technology
Standing Member of Professional Committee of Radiological Medicine of the Chinese People’s Liberation Army
Standing Editorial Board Member and Editorial Board Member of Journal of Interventional Radiology
Awarded the Special Government Allowance of the State Council
Awarded three Second Prizes and four Third Prizes for Military Science and Technology Progress.
Awarded the honorary title of “Chinese College of Interventionalists(CCI) Master Interventionalist”
Led multiple national and provincial/ministerial scientific research projects, including two projects funded by the National Natural Science Foundation of China and two projects funded by the Department of Science and Technology of Sichuan Province.
In the pioneering development of interventional medicine in China, Zhang Jinshan has been an indispensable founder and leading figure. As China’s first overseas-trained doctoral graduate in radiological medicine, he returned to China in the 1980s after completing his studies abroad and introduced cutting-edge international interventional technologies to the country. Over more than four decades of dedicated practice and research, he has helped propel Chinese interventional medicine from its infancy to a position at the forefront of the global field through his exceptional clinical expertise and profound academic accomplishments.
Professor Zhang Jinshan has long been dedicated to the field of medical imaging and has developed distinctive expertise in selective and superselective interventional diagnosis and treatment for solid tumors such as liver cancer, demonstrating exceptional technical proficiency and profound academic accomplishment. Beginning in the 1990s, he led his team in pioneering the clinical application and research of TIPSS and B-ORTO in China, filling major gaps in the domestic field and opening new paths for the interventional management of gastrointestinal bleeding caused by portal hypertension secondary to liver cirrhosis. In addition, he has made groundbreaking contributions to the interventional diagnosis and treatment of peripheral vascular diseases, as well as to preoperative embolization for spinal tumors.
In the field of liver cancer treatment, Professor Zhang Jinshan not only led the development of standardized treatment protocols for liver cancer but also pioneered Transcatheter Arterial Chemoembolization with temporary Hepatic Vein Thrombosis (TACE-THVO) for primary liver cancer, bringing the efficacy of interventional therapy to a new level. In recognition of his outstanding clinical and scientific contributions, he was awarded the honorary title of “Chinese Master of Interventional Radiology” at the 2019 annual conference of the Chinese College of Interventionalists.
Professor Zhang Jinshan is not only a master clinician but also a driving force in the development of the discipline and a dedicated mentor in talent cultivation. He led his team in establishing one of China’s premier interventional therapy centers. As a doctoral supervisor, he has trained a large number of outstanding specialists and future leaders in interventional medicine, with many of his students and protégés now serving across the country. Academically, he has led multiple key national and military research projects, published more than 300 academic papers, and served as chief editor of three monographs, making remarkable contributions to the establishment of China’s academic framework for interventional medicine and the nationwide dissemination of its technologies.
From the laboratory to the operating room, and from academic podiums to grassroots hospitals, Professor Zhang Jinshan has consistently upheld the principles of “pioneering, innovation, pragmatism, and compassion". He has devoted his life to fulfilling the mission of a physician—relieving patients’ suffering through minimally invasive techniques and advancing the discipline through academic excellence—thereby establishing himself as a truly towering figure and one of the foremost authorities in the field of interventional medicine in China.
Professor Zhang Jinshan has achieved prolific academic accomplishments, having published over 300 academic papers covering areas such as interventional therapy for liver cancer, minimally invasive treatment of portal hypertension, interventional treatment of vascular diseases, and tumor ablation.
1. Zhang Jinshan, Wang Maoqiang. Experiments and Clinical Studies of transjugular intrahepatic portosystemic stent shunt (TIPSS). Chinese Journal of Radiology, 1993，27（6）：361-365.
Professor Zhang Jinshan is the first author. This is one of the early research papers in China that systematically elaborates on the TIPSS technique. Through animal experiments and clinical case analysis, it confirmed that TIPSS is a safe and effective minimally invasive method for treating portal hypertension and its complications, laying an important foundation for the promotion and application of this technique in China.
2.Zhang Jinshan, Li Huai. Clinical study on transcatheter arterial embolization with temporary hepatic vein occlusion for the treatment of primary liver cancer.Chinese Journal of Radiology, 1996，30（8）：521-524.
Professor Zhang Jinshan is the first author. He innovatively proposed the technique of "transcatheter arterial embolization with temporary hepatic vein occlusion." Clinical results demonstrated that this method can significantly increase the drug concentration within liver cancer lesions, reduce damage to normal liver tissue, and effectively improve the therapeutic outcomes for intermediate and advanced liver cancer, providing a novel strategy for the interventional treatment of liver cancer.
3. Zhang Jinshan, Wang Maoqiang, Li Huai. Interventional treatment of Budd-Chiari syndrome. Chinese Journal of Medical Imaging Technology, 1998，14（3）：189-191.
Professor Zhang Jinshan is the first author. This paper systematically summarizes the early experience in interventional treatment of Budd-Chiari syndrome in China, elaborating in detail on the key operational points and therapeutic efficacy of techniques such as percutaneous transluminal angioplasty and stent placement. It confirms that interventional therapy is the preferred minimally invasive method for Budd-Chiari syndrome, promoting the standardized development of treatment for this disease.
4.Zhang Jinshan, Li Huai, Wang Maoqiang. Clinical value of superselective hepatic arterial chemoembolization in the treatment of hypovascular liver cancer. Chinese Journal of Radiology, 2000，34（5）：335-337.
Professor Zhang Jinshan is the first author. Addressing the challenges in interventional treatment of hypovascular liver cancer, this paper explores the clinical efficacy of superselective hepatic arterial chemoembolization. The results indicate that this technique can precisely target the lesions and improve the treatment response rate, providing an important clinical basis for the interventional treatment of hypovascular liver cancer.
5. Zhang Jinshan, Li Huai, Wang Maoqiang. Interventional treatment of peripheral vascular stenosis and occlusion.Chinese Journal of Radiology, 2002，36（7）：612-614.
Professor Zhang Jinshan is the first author. This paper summarizes the interventional treatment experience of over 400 patients with peripheral vascular stenosis and occlusion, analyzing the indications and efficacy of techniques such as balloon angioplasty and stent placement. It confirms that interventional therapy is a safe and effective approach for peripheral vascular diseases, providing practical support for its clinical promotion.
6.Zhang Jinshan, Li Huai, Wang Maoqiang. Clinical application of CT-guided percutaneous puncture ablation in the treatment of abdominal tumors. Chinese Journal of Medical Imaging Technology, 2004，20（9）：1395-1397.
Professor Zhang Jinshan is the first author. This paper explores the application value of CT-guided percutaneous puncture techniques such as radiofrequency ablation and chemical ablation in the treatment of abdominal tumors. The clinical results show that this method is minimally invasive with reliable efficacy, offering a minimally invasive treatment option for patients with inoperable abdominal tumors.
7.Zhang Jinshan, Wang Maoqiang, Li Huai. Advances in the application of interventional therapy for benign prostatic hyperplasia. Chinese Journal of Radiology, 2006，40（8）：876-878.
Professor Zhang Jinshan is the corresponding author. This paper systematically reviews the cutting-edge advances in interventional therapy for benign prostatic hyperplasia, including the principles, procedures, and efficacy of techniques such as prostatic artery embolization and stent placement, providing new insights for the minimally invasive treatment of benign prostatic hyperplasia.
8.Zhang Jinshan, Li Huai, Wang Maoqiang. Discussion on the standardization of interventional therapy for liver cancer. Chinese Journal of Practical Surgery, 2008，28（10）：856-858.
Professor Zhang Jinshan is the corresponding author. Drawing on years of clinical experience and research findings, he led the discussion on standardized protocols for interventional therapy of liver cancer, covering key aspects such as preoperative assessment, treatment modality selection, and postoperative management, providing important references for the formulation of clinical guidelines for interventional therapy of liver cancer in China.
1. Interventional Radiology (People's Military Medical Press, 1995): The first monograph in China to systematically discuss the theories and techniques of interventional radiology. It comprehensively elaborates on the interventional diagnosis and treatment system for tumors, vascular diseases, and non-vascular diseases, becoming a classic essential textbook for interventional physicians in China.
2.Interventional Therapy for Liver Cancer (People's Health Press, 2001): Focusing on minimally invasive interventions for liver cancer, this book systematically summarizes techniques such as TACE, ablation, and vascular intervention, refines operational standards and the prevention and management of complications, and promotes the standardization of interventional therapy for liver cancer.
3.Interventional Treatment of Portal Hypertension (Science Press, 2005): This book systematically elaborates on minimally invasive techniques for portal hypertension, such as TIPSS and B-ORTO, covering experimental research, clinical procedures, long-term follow-up, and efficacy evaluation, filling the gap in monographs on interventional treatment of portal hypertension in China.
1.The National "Eighth Five-Year Plan" Scientific and Technological Key Project—Clinical and Basic Research on Comprehensive Interventional Therapy for Liver Cancer (Project Leader): This project systematically explored multimodal interventional strategies for liver cancer, established the core regimen of superselective TACE combined with local ablation, and significantly improved the therapeutic outcomes for intermediate and advanced liver cancer.
2.The Military "Ninth Five-Year Plan" Key Medical Scientific Research Project—Standardized Research on TIPSS for the Treatment of Portal Hypertension (Project Leader): This project formulated China's first operational standards and postoperative management guidelines for TIPSS, reduced the incidence of complications, and promoted the popularization of this technique throughout the military and across the country.
3.National Natural Science Foundation of China Project — Research on the Mechanism of Targeted Therapy for Liver Cancer Using Hepatic Vein Occlusion Combined with Chemoembolization (Project Leader): This project revealed the synergistic enhancement mechanisms of the innovative technique at the levels of hemodynamics, drug metabolism, and the tumor microenvironment, providing theoretical support for precision interventional therapy of liver cancer.
4.Military Clinical High-Tech Major Project-Establishment and Clinical Application of the Interventional Treatment Technology System for Complex Vascular Diseases (Project Leader): This project overcame interventional challenges in complex lesions such as Budd-Chiari syndrome, peripheral vascular occlusion, and vascular malformations, forming a complete technical system that has been promoted and applied widely.
Boursi教授は、シェバ医療センターで消化器腫瘍学を専門としています。ガリウム68を用いたPET-CTなどの詳細な画像診断を使用して、神経内分泌腫瘍を発見します。
ニール・クラインマン医師は、シェバ医療センターの結石・内視鏡泌尿器科ユニットを統括しています。複雑な腫瘍に対する腎温存レーザー手術のパイオニアです。フォーブス誌とResultMedにより、2025年および2026年のイスラエルのベストドクターに選出されました。クラインマン医師は、がん治療中に臓器機能を維持するための独自のデュアルレーザーシステムを使用しています。
ギル・ラヴィヴ教授は、シェバ医療センターの男性医学（アンドロロジー）および再建泌尿器科の専門医です。フォーブス誌によりイスラエルのベストドクターの一人に選ばれました。アンドロロジー部門の部長を務めています。ラヴィヴ医師は、男性不妊症、性機能の健康、尿道再建に注力しています。世界トップ10にランクされるシェバ医療センターで勤務しています。
ヤイール・バー博士は、シェバ医療センターの癌センターの副所長であり、胸部腫瘍内科医です。進行非小細胞肺癌の治療において、個別化免疫療法および標的療法を専門としています。分子生物学の博士号（PhD）を取得しており、免疫療法耐性に焦点を当てた研究室を主導しています。